Neuraxpharm Group Archives

Home Neuraxpharm Group

Latest Posts

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

More News! 26 Oct 2022

Neuraxpharm to commercialize device giving early warning of epileptic seizures

A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]

October 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 13 Jul 2022

Sanofi sells two portfolios of established products to Neuraxpharma

Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from French healthcare company, Sanofi. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven […]

July 13, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us